Welcome!

News Feed Item

Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

NEW YORK, Jan. 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0843003/Urinary-Tract-Infections-UTI-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy  

Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Urinary Tract Infections Therapeutics market. The report identifies the key trends shaping and driving the global Urinary Tract Infections Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Urinary Tract Infections Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Urinary Tract Infections Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Urinary Tract Infections Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Urinary Tract Infections Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Urinary Tract Infections Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Urinary Tract Infections Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Urinary Tract Infections Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Urinary Tract Infections Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Urinary Tract Infections Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 UTI Therapeutics - Introduction 72.1 Overview 72.2 Classification of UTI 72.2.1 Site of Infection 82.2.2 Based On Symptoms 82.2.3 Based on Recurrence 82.2.4 Based on Complicating Factors 82.2.5 Based on Origin of Infection 82.3 Epidemiology 92.4 Etiology 102.5 Risk Factors 102.6 Signs and Symptoms 112.7 Pathophysiology of UTI 112.8 Diagnosis and Treatment of UTI 122.9 GlobalData Pipeline Report Guidance 163 UTI Therapeutics - Market Characterization 173.1 UTI Therapeutics Market Size (2005-2010) - Global 173.2 UTI Therapeutics Market Forecast (2010-2018) - Global 193.3 UTI Therapeutics Market Size (2005-2010) - The US 213.4 UTI Therapeutics Market Forecast (2010-2018) - The US 223.5 UTI Therapeutics Market Size (2005-2010) - France 233.6 UTI Therapeutics Market Forecast (2010-2018) - France 243.7 UTI Therapeutics Market Size (2005-2010) - Germany 253.8 UTI Therapeutics Market Forecast (2010-2018) - Germany 263.9 UTI Therapeutics Market Size (2005-2010) - Italy 273.10 UTI Therapeutics Market Forecast (2010-2018) - Italy 283.11 UTI Therapeutics Market Size (2005-2010) - Spain 293.12 UTI Therapeutics Market Forecast (2010-2018) - Spain 303.13 UTI Therapeutics Market Size (2005-2010) - The UK 313.14 UTI Therapeutics Market Forecast (2010-2018) - The UK 323.15 UTI Therapeutics Market Size (2005-2010) - Japan 333.16 UTI Therapeutics Market Forecast (2010-2018) - Japan 343.17 Drivers and Barriers for the UTI Therapeutics Market 353.17.1 Drivers for the UTI Therapeutics Market 353.17.2 Barriers for the UTI Therapeutics Market 353.18 Key Events Impacting the Future Market 363.19 Opportunity and Unmet Need 363.20 Key Takeaway 374 UTI Therapeutics Market - Competitive Assessment 384.1 Overview 384.1.1 Strategic Competitor Assessment 384.2 Profiles of Commonly Used Products in the UTI Therapeutics Market 394.2.1 Ciprofloxacin 394.2.2 Doribax (doripenem) 404.2.3 Invanz (ertapenem sodium) 414.2.4 Levaquin (levofloxacin) 424.2.5 Fosfomycin tromethamine 424.2.6 Macrobid/Macrodantin (nitrofurantoin) 434.2.7 Bactrim/Septra (trimethoprim/sulfamethoxazole) 444.3 Key Takeaway 445 UTI Therapeutics Market - Pipeline Assessment 455.1 Overview 455.2 Strategic Pipeline Assessment 455.2.1 UTI Therapeutics - Phase III Pipeline 465.2.2 UTI Therapeutics - Phase II Pipeline 465.2.3 UTI Therapeutics – Phase I Pipeline 465.3 UTI Pipeline by Mechanism of Action 475.4 UTI Technology Trends Analytical Framework 485.5 UTI Therapeutics - Late-stage Drugs under Clinical Development 495.6 Molecule Profile for Late-stage Drugs under Clinical Development 505.6.1 CXA-201 (CXA-101/tazobactam) 505.6.2 CAZ-AVI (Avibactam/ceftazidime) 505.7 Key Takeaway 516 UTI Therapeutics - Clinical Trials Mapping 526.1 Clinical Trials by Country (US, EU5 and Japan) 526.2 Clinical Trials by Phase 536.3 Clinical Trials by Trial Status 546.4 Overall Sponsors 556.5 Prominent Sponsors 566.6 Top Companies Participating in UTI Therapeutics Clinical Trials 577 UTI Therapeutics - Strategic Assessment 587.1 UTI Therapeutics - Implications for Future Market Competition 588 UTI Therapeutics - Future Players 598.1 Introduction 598.1.1 AstraZeneca PLC 598.1.2 Cubist Pharmaceuticals 618.1.3 Forest Laboratories 639 UTI Therapeutics - Licensing and Partnership Deals 6510 UTI Therapeutics - Appendix 6710.1 Definitions 6710.2 Acronyms 6710.3 Research Methodology 6810.3.1 Coverage 6810.3.2 Secondary Research 6810.3.3 Forecasting 6910.3.4 Primary Research 7110.3.5 Expert Panel Validation 7110.4 Contact Us 7110.5 Disclaimer 7110.6 Bibliography 72

List of Tables

Table 1: UTI - Prevalence, Major Markets, 2010 9Table 2: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010 17Table 3: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018 19Table 4: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010 21Table 5: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018 22Table 6: UTI Therapeutics Market, France, Revenue ($m), 2005-2010 23Table 7: UTI Therapeutics Market, France, Forecast ($m), 2010-2018 24Table 8: UTI Therapeutics Market, Germany, Revenue ($m), 2005-2010 25Table 9: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018 26Table 10: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010 27Table 11: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018 28Table 12: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010 29Table 13: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018 30Table 14: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010 31Table 15: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018 32Table 16: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010 33Table 17: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018 34Table 18: UTI Therapeutics - Phase III Pipeline 46Table 19: UTI Therapeutics - Phase II Pipeline 46Table 20: UTI Therapeutics – Phase I Pipeline 46Table 21: UTI Therapeutics - Late-stage Drugs Under Clinical Development, 2011 49Table 22: UTI Therapeutics - Clinical Trials by Country, 2011 52Table 23: UTI Therapeutics - Clinical Trials by Phase, 2011 53Table 24: UTI Therapeutics - Clinical Trials by Status, 2011 54Table 25: UTI Therapeutics, Overall Sponsors, 2011 55Table 26: UTI Therapeutics - Prominent Sponsors, 2011 56Table 27: UTI Therapeutics - Top Companies Participating in Clinical Trials, 2011 57Table 28: AstraZeneca Infectious Disease Pipeline, 2011 61Table 29: Cubist Pharmaceuticals Infectious Disease Pipeline, 2011 62Table 30: Forest Laboratories - Infectious Disease Pipeline, 2011 64Table 31: Licensing and Partnership Deals 65

List of Figures

Figure 1: Classification of UTI 7Figure 2: Principal Pathogens of UTI 10Figure 3: Symptoms of UTI 11Figure 4: Diagnostic Approach to UTI in Adults 12Figure 5: Different Class of Antibiotics Used for UTI 13Figure 6: Diagnosis and Treatment of UTI 14Figure 7: Diagnosis and Treatment of UTI 15Figure 8: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010 17Figure 9: UTI Therapeutics, Market Share ($m, %), 2010 18Figure 10: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018 19Figure 11: UTI Therapeutics, Market Share ($m, %), 2018 20Figure 12: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010 21Figure 13: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018 22Figure 14: UTI Therapeutics Market, France, Revenue ($m), 2005-2010 23Figure 15: UTI Therapeutics Market, France, Forecast ($m), 2010-2018 24Figure 16: UTI Therapeutics Market, Germany , Revenue ($m), 2005-2010 25Figure 17: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018 26Figure 18: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010 27Figure 19: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018 28Figure 20: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010 29Figure 21: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018 30Figure 22: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010 31Figure 23: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018 32Figure 24: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010 33Figure 25: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018 34Figure 26: UTI Therapeutics Market , Key Events Impacting the Future Market 36Figure 27: Opportunity and Unmet Need in the UTI Therapeutics Market, 2011 37Figure 28: UTI Therapeutics - Strategic Competitor Assessment, 2011 39Figure 29: UTI Therapeutics - Pipeline by Phase of Clinical Development, 2011 45Figure 30: UTI Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011 47Figure 31: Technology Trends Analytical Framework of the UTI Pipeline, 2011 48Figure 32: Technology Trends Analytical Framework of The UTI Therapeutics Pipeline - Description, 2011 49Figure 33: UTI Therapeutics - Clinical Trials by Country, 2011 52Figure 34: UTI Therapeutics - Clinical Trials by Phase, 2011 53Figure 35: UTI Therapeutics - Clinical Trials by Status, 2011 54Figure 36: UTI Therapeutics - Overall Sponsors, 2011 55Figure 37: UTI Therapeutics - Prominent Sponsors, 2011 56Figure 38: UTI Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 57Figure 39: Implications for Future Market Competition in the UTI Therapeutics Market, 2011 58Figure 40: UTI Therapeutics Market - Clinical Pipeline by Company, 2011 59Figure 41: GlobalData Market Forecasting Model 70

Companies mentioned

AstraZeneca PLC

Cubist Pharmaceuticals

Forest Laboratories

To order this report: Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection. In his session at 18th Cloud Expo, Bradley Holt, a Developer Advocate with IBM Cloud Data Services, discussed...
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
According to Forrester Research, every business will become either a digital predator or digital prey by 2020. To avoid demise, organizations must rapidly create new sources of value in their end-to-end customer experiences. True digital predators also must break down information and process silos and extend digital transformation initiatives to empower employees with the digital resources needed to win, serve, and retain customers.
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, discussed using predictive analytics to mon...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...